3 ms·
The trial can, and should, be double-blinded. With psychedelics, both the patient and observer know if they've received psychedelics vs. placebo. That's often
by PragmaticPulp 7y ago
The trial can, and should, be double-blinded. With psychedelics, both the patient and observer know if they've received psychedelics vs. placebo.
That's often used an excuse to perform studies without control groups, which is not a valid argument. There must always be a control group. That's one of the main flaws in this study.
As for considering the studies specious: Not true. If the active group has considerably improved scores relative to the control group, then it doesn't really matter if they know they received true psychedelic drugs. In fact, some of the downstream effects might be due to psychedelics acting as a sort of super placebo.
If someone tells you they're giving you psychedelics to study antidepressant effects and then you spend the next 12 hours tripping, you're going to feel that something profound has happened. Being primed to expect improvements in depression and anxiety combined with the extreme disorientation of a psychedelic might be enough to elicit the antidepressant response.
- pmoriarty 7y ago"With psychedelics, both the patient and observer know if they've received psychedelics vs. placebo." That's not necessarily true. With MDMA, which can arguably be considered a psychedelic, some people who were given a placebo during the research studies swore they got MDMA, and had very productive sessions. Some people also don't hallucinate even on psychedelics like LSD, which usually cause visual hallucinations, so even with those it's possible for placebos to be effective. Rick Doblin originally designed his MDMA studies to use a lower dose of MDMA as a placebo, but found that it actually tended to make people with PTSD worse than using an inactive placebo (because the small dose would be enough to bring up old trauma, but not large enough for the people to feel safe in dealing with it, so they re-buried the trauma after being re-traumatized with it, making them worse), so he gave the FDA the choice of using the active placebo and making subjects worse or using the inactive placebo and not making them worse but giving up the double-blind nature of the trial, and they chose the latter.